A drug that AstraZeneca singled out as one of its key potential revenue growth drivers in the next decade has failed a pivotal study in light chain amyloidosis, a rare disease with few treatment ...
Increased Serum Free Light Chains Precede the Presentation of Immunoglobulin Light Chain Amyloidosis
Patients with immunoglobulin light chain amyloidosis (AL amyloidosis) generally present with advanced organ dysfunction and have a high risk of early death. We sought to characterize monoclonal ...
Please provide your email address to receive an email when new articles are posted on . EMPHASIS study included 258 persons with MS given vidofludimus calcium or placebo for 24 weeks. Results show ...
On June 12th, 2023 local time, Sanyou Biopharmaceuticals Co., Ltd. officially announced the launch of "Sanyou Super Trillion Common Light Chain Antibody Discovery Platform" (the "platform"). As one of ...
Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia The AL-ISS enables clinicians to ...
AL (immunoglobulin light chain) amyloidosis is a rare disease that often results in progressive organ dysfunction, organ failure and eventual death. Clonal plasma cells in the bone marrow secrete free ...
Antibodies hold promise as therapeutic agents. However, their tendency to aggregate poses significant challenges to drug development. In a groundbreaking study, researchers now provide novel insights ...
Please provide your email address to receive an email when new articles are posted on . “Teclistamab has already been approved in multiple myeloma, and there is institutional data where it shows that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results